Lexeo CFO receives 54,750 stock options

Twenty-five percent becomes exercisable on September 24, 2027, with monthly vesting thereafter subject to continuous service.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Financial Officer Louis Edward Tamayo received a direct grant of 54,750 stock options on September 24, 2026, covering 54,750 shares of common stock and exercisable at $3.39 per share. Twenty-five percent of the underlying shares vest and become exercisable on September 24, 2027; 1/48th vests in monthly installments thereafter, subject to his continuous service. The options expire September 23, 2036.

Insider Trade Summary

Grant/Award: 54,750 shares

Grant/Award 1 txn

Insider Tamayo Louis Edward

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	54,750	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 54,750 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Key Figures

Stock options granted: 54,750 options Underlying common stock: 54,750 shares Exercise price: $3.39 per share +3 more

6 metrics

Stock options granted 54,750 options Direct grant on September 24, 2026

Underlying common stock 54,750 shares Shares underlying the options

Exercise price $3.39 per share Option terms

Initial vesting 25% Vests and becomes exercisable on September 24, 2027, subject to continuous service

Monthly vesting 1/48th of the underlying shares Monthly installments thereafter, subject to continuous service

Expiration date September 23, 2036 Option expiration

Key Terms

vest, exercisable, exercise price, continuous service

4 terms

vest financial

"shares underlying the option vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercisable financial

"vest and become exercisable"

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the Reporting Person's continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did LXEO CFO Louis Edward Tamayo receive?

Louis Edward Tamayo, Lexeo Therapeutics, Inc.'s Chief Financial Officer, received a direct grant of 54,750 stock options on September 24, 2026, covering 54,750 shares of common stock. The options have an exercise price of $3.39 per share.

When do LXEO's newly granted options vest?

Twenty-five percent of the shares underlying the options vest and become exercisable on September 24, 2027. After that, 1/48th of the underlying shares vest in monthly installments, subject to Louis Edward Tamayo's continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 05:15 PM Accepted by SEC EDGAR 09/28/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tamayo Louis Edward

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.39	09/24/2026		A		54,750		(1)	09/23/2036	Common Stock	54,750	$0	54,750	D

Explanation of Responses:

1. 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Youjin Choi, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)